IHC Tumor Markers: Key Tools for Gastric and Colorectal Cancer Diagnosis and ANTBIO's Antibody Solutions

1. Concept: Immunohistochemical (IHC) Tumor Markers in Gastrointestinal Cancers

Immunohistochemical (IHC) tumor markers are specific biomolecules—predominantly proteins—whose abnormal expression in tumor tissues serves as critical indicators for cancer research and clinical practice. IHC technology leverages the specificity of antigen-antibody binding to visualize these markers in histological sections, enabling qualitative, semi-quantitative, and spatial analysis of their distribution. In gastric and colorectal cancers, IHC tumor markers play a pivotal role in distinguishing malignant lesions from benign tissues, subclassifying tumor types, evaluating biological behaviors (e.g., invasiveness, metastatic potential), and guiding targeted therapy selection. As a cornerstone of pathological diagnosis, IHC bridges basic research and clinical decision-making, providing actionable insights for precision oncology in gastrointestinal malignancies.

2. Research Frontiers of IHC Tumor Markers in Gastric and Colorectal Cancers

Recent advancements in gastrointestinal cancer research have propelled the evolution of IHC tumor marker applications. A prominent frontier is the validation of novel therapeutic targets-turned-markers, with Claudin 18.2 emerging as a top candidate in gastric cancer. Its high selectivity for tumor tissues has made it a focus for both diagnostic antibody development and targeted drug research, complementing established targets like HER2. Another key direction is the adoption of multi-marker IHC panels (e.g., CDX2 + MSH6 + p53) to improve the accuracy of differential diagnosis and prognosis prediction, addressing the limitations of single-marker detection in complex cases. Additionally, standardization of IHC protocols and interpretation criteria—particularly for mismatch repair (MMR) proteins like MSH6—has become a priority to ensure consistency across laboratories, facilitating reliable assessment of Lynch syndrome risk in colorectal cancer patients. Furthermore, the integration of IHC data with genomic profiling is enabling the identification of patient subgroups responsive to immunotherapy or targeted agents, advancing personalized treatment strategies.

3. Research Significance of IHC Tumor Markers in Gastric and Colorectal Cancers

Gastric and colorectal cancers are among the most prevalent malignancies globally, with high mortality rates attributed to late diagnosis and limited treatment options for advanced disease. IHC tumor markers address critical unmet needs in both research and clinical practice:

• Early detection and diagnosis: Aberrant expression of markers such as Claudin 18.2 and Gastrin aids in identifying precancerous lesions and distinguishing malignant from benign gastrointestinal polyps, enabling timely intervention.
• Tumor classification and differential diagnosis: Markers like CDX2 (a key intestinal differentiation marker) help distinguish colorectal cancer from other metastatic tumors, while Claudin 18.2 facilitates the subclassification of gastric cancer subtypes.
• Therapy guidance: Detection of Claudin 18.2 overexpression identifies patients eligible for Claudin 18.2-targeted therapies, while MSH6 deficiency (indicating MMR dysfunction) predicts responsiveness to immune checkpoint inhibitors.
• Prognosis assessment and risk stratification: Abnormal p53 expression correlates with poor prognosis in both gastric and colorectal cancers, guiding clinicians in optimizing follow-up strategies and treatment intensity.
• Basic research advancement: IHC markers provide insights into the molecular mechanisms driving gastrointestinal cancer progression, supporting the development of novel therapeutic targets and diagnostic tools.

4. Relevant Mechanisms, Research Methods and Product Applications

4.1 Core Mechanisms of Key IHC Markers in Gastric and Colorectal Cancers

Claudin 18.2

Claudin 18.2, encoded by the CLDN18 gene, is a member of the claudin protein family that forms tight junctions in epithelial cells. As an isoform of Claudin 18, it exhibits restricted expression in normal gastric mucosa but is aberrantly overexpressed in gastric cancer cells, where it contributes to tumor cell adhesion, invasion, and metastasis. Its exposed extracellular loops make it an ideal target for monoclonal antibodies, enabling both diagnostic detection and targeted therapy.

Gastrin

Gastrin, a peptide hormone, regulates gastric acid secretion, pancreatic enzyme release, and gastrointestinal motility under physiological conditions. In gastric cancer, dysregulated gastrin expression is associated with increased proliferation of gastric epithelial cells and the development of gastrin-secreting tumors (gastrinomas). Detection of gastrin via IHC aids in identifying G-cell hyperplasia and gastrinoma, supporting research on hormone-driven carcinogenesis.

CDX2

CDX2, a homeobox transcription factor encoded by the CDX2 gene, is a master regulator of intestinal epithelial development and differentiation. It is constitutively expressed in colorectal cancer cells, where it maintains intestinal phenotypic characteristics. Loss of CDX2 expression is associated with poorly differentiated tumors and adverse prognosis, making it a key marker for confirming colorectal origin in metastatic cancers.

MSH6

MSH6 is a DNA mismatch repair (MMR) protein that forms a heterodimer with MSH2 to recognize and repair base substitutions and single-base insertions/deletions. Germline mutations in the MSH6 gene impair MMR function, increasing the risk of Lynch syndrome (a hereditary cancer predisposition syndrome) and colorectal, endometrial, and other cancers. IHC detection of MSH6 deficiency (loss of expression) is a critical screening tool for Lynch syndrome.

p53

p53, a tumor suppressor protein encoded by the TP53 gene, regulates cell cycle arrest, apoptosis, and DNA repair. Mutations in TP53 are frequent in gastric and colorectal cancers, leading to the expression of dysfunctional p53 protein. Abnormal p53 expression (overexpression or loss) correlates with increased tumor aggressiveness, chemotherapy resistance, and poor patient survival.

4.2 Key Research Methods for IHC Tumor Marker Detection

The standard workflow for IHC analysis in gastric and colorectal cancer research includes:

• Sample preparation: Formalin-fixed paraffin-embedded (FFPE) tissue sections (the gold standard for clinical specimens) or fresh frozen samples are processed to preserve antigen integrity.
• IHC staining protocol: Deparaffinization, antigen retrieval (heat-induced or enzyme-mediated), blocking of non-specific binding sites, incubation with primary antibodies (targeting markers like Claudin 18.2, CDX2, MSH6), binding with enzyme-conjugated secondary antibodies (e.g., horseradish peroxidase), chromogenic reaction, and counterstaining with hematoxylin.
• Result interpretation: Qualitative assessment (positive/negative expression) and semi-quantitative scoring (based on staining intensity and percentage of positive cells) using light microscopy or image analysis software.
• Validation: Correlation of IHC results with clinical outcomes (e.g., survival, treatment response) or molecular data (e.g., gene mutations) to confirm marker utility.

4.3 Product Applications of ANT BIO PTE. LTD.

ANT BIO PTE. LTD. delivers tailored IHC antibody solutions for gastric and colorectal cancer research through its Starter sub-brand—specializing in high-performance antibodies. All products are developed using advanced recombinant rabbit monoclonal antibody platforms, ensuring exceptional specificity, sensitivity, and reproducibility, and have passed rigorous quality control in compliance with EU 98/79/EC, ISO9001, and ISO13485 certifications. Key products include:

• Claudin 18.2 Recombinant Rabbit mAbs: Catalog numbers S0B2070 (S-RMab® SDT-102-83) and S0B2069 (SDT-102-24) offer outstanding performance with high specificity (no cross-reactivity with Claudin 18.1), precise membrane staining (minimal non-specific background), and clear intensity gradients. Validated across gastric, lung, and colorectal cancer samples, these antibodies support accurate detection of Claudin 18.2 expression for diagnostic and therapeutic research.
• CDX2 Recombinant Rabbit mAb (S0B2079, SDT-134-76): Specifically targets the CDX2 transcription factor, enabling reliable identification of intestinal differentiation in colorectal cancer and differential diagnosis of metastatic tumors.
• MSH6 Recombinant Rabbit mAb (S0B2110, S-RMab® SDT-R094): Facilitates the detection of MSH6 expression, supporting MMR deficiency screening and Lynch syndrome risk assessment in colorectal cancer patients.
• Gastrin Recombinant Rabbit mAb (S0B2094, SDT-R068): Ideal for identifying gastrin-secreting cells, aiding research on G-cell proliferation and gastrinoma development.
• p53 Recombinant Rabbit mAb (S0B2146, S-RMab® SDT-R118): Enables accurate assessment of p53 expression, supporting prognosis evaluation and chemotherapy response prediction.
• ErbB2/HER2 Recombinant Rabbit mAb (S0B2078, SDT-069-10): Targets the HER2 oncoprotein, complementing Claudin 18.2 research in gastric cancer targeted therapy.
• Villin Recombinant Rabbit mAb (S0B2017, S-RMab® SDT-039-78): A marker for intestinal epithelial cells, supporting the differential diagnosis of gastrointestinal cancers.

These antibodies have been widely adopted by researchers and pathologists globally, contributing to precise marker detection and advancing gastric and colorectal cancer research and clinical diagnosis.

5. Brand Mission of ANT BIO PTE. LTD.

ANT BIO PTE. LTD. is dedicated to empowering global life science research and clinical practice through high-quality, innovative reagents and professional services. As a leading provider of life science solutions, the company offers a comprehensive portfolio including antibodies, recombinant proteins, ELISA kits, and general laboratory reagents, with three specialized sub-brands: Absin (general reagents and kits), Starter (antibodies), and UA (recombinant proteins). Leveraging advanced R&D platforms—including recombinant antibody development (rabbit/mouse monoclonal), protein expression systems (E.coli, CHO, HEK293, Insect Cells), One-Step ELISA, and PTM Pan-Modification Antibody platforms—ANT BIO PTE. LTD. adheres to the principles of "precision, reliability, and customer-centricity." The company strives to deliver cost-effective products and tailored support to researchers, clinicians, and biopharmaceutical partners, accelerating the translation of scientific discoveries into improved patient care and advancing the global fight against cancer.

6. Related Product List

7. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.